# Platinum-based Chemotherapy With Atezolizumab and Niraparib in Patients With Recurrent Ovarian Cancer

> **NCT03598270** · PHASE3 · COMPLETED · sponsor: **Grupo Español de Investigación en Cáncer de Ovario** · enrollment: 417 (actual)

## Conditions studied

- Recurrent Ovarian Carcinoma

## Interventions

- **DRUG:** Placebo
- **DRUG:** Carboplatin
- **DRUG:** Paclitaxel
- **DRUG:** Niraparib
- **DRUG:** Gemcitabine
- **DRUG:** Pegylated liposomal doxorubicin (PLD)
- **DRUG:** Atezolizumab

## Key facts

- **NCT ID:** NCT03598270
- **Lead sponsor:** Grupo Español de Investigación en Cáncer de Ovario
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-11-21
- **Primary completion:** 2024-08-05
- **Final completion:** 2024-08-05
- **Target enrollment:** 417 (ACTUAL)
- **Last updated:** 2024-08-30

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03598270

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03598270, "Platinum-based Chemotherapy With Atezolizumab and Niraparib in Patients With Recurrent Ovarian Cancer". Retrieved via MORVS 2026-10-18 from https://api.morvs.ai/clinical/NCT03598270. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*